Private Equity
For many U.S. -based startups, European privacy standards remain an afterthought. To find out why that's so dangerous, we called up Phil Lee, a freshly-arrived-to-Silicon Valley attorney who heads up the U.S. practice of London-based Field Fisher Waterhouse, and who specializes in helping U.S. companies understand the black box that is European privacy law.
8 min read · 30 November 2012
U.S. daily deals online firm Living Social Inc is expected to announce on Thursday it is cutting 400 jobs, representing 9 percent of its workforce, as demand for daily deals and emailed daily discounts dries up, the Wall Street Journal reported, citing a source familiar with the plans.
1 min read · 29 November 2012
Mohr Davidow Ventures says it is charting a course away from the cleantech and life sciences investing of the past several years and back to the firm’s information technology roots.
3 min read · 29 November 2012
An overview of Canada’s Venture Capital Market in Q3 2012, produced by Thomson Reuters for Canada's Venture Capital & Private Equity Association
1 min read · 28 November 2012
Sanu Desai probably knows venture-backed M&A as well as any investment banker, and as the year winds down, we asked for Desai’s perspective on the sluggish tech M&A market, private company valuations and what sectors he expects will drive deals in 2013.
4 min read · 28 November 2012
It is not an easy time to be a cleantech venture capitalist. Still a hardened group of investors presses on. A handful of these determined GPs talk about what keeps them going.
2 min read · 28 November 2012
Entrepreneurs get absorbed into big companies every day when their startups are acquired. When they eventually leave, as so many do, the smart ones exit gracefully. You can put Tobias Peggs in that camp; here's why.
10 min read · 28 November 2012
Halifax, Nova Scotia-based LeadSift, a start-up that mines social media data to generate high-quality sales leads, has secured $500,000 in financing from OMERS Ventures. The money will go toward sales and marketing efforts, as well as continued product development.
3 min read · 27 November 2012
Third quarter venture deal making saw a softening of early and growth stage valuations, but a continued high level of competition in later rounds. Median pre-money valuations fell in Series A and B deals, and up rounds across all stages of venture financing slumped modestly to 71% of deals compared with 77% in the second quarter, the law firm Cooley reports.
1 min read · 27 November 2012
MethylGene Inc., a Montreal-based biopharmaceuticals firm, announced the completion of a new financing totaling C$26.1 million. The investment was led by Tavistock Life Sciences, a company insider, and included OrbiMed Advisors LLC, Tang Capital Partners LP, RA Capital Management and BVF Partners LP .
4 min read · 26 November 2012
